Long-term safety of apremilast treatment in patients with psoriasis or psoriatic arthritis: Pooled analysis for 260 weeks and beyond in the ESTEEM 1 and 2 and PALACE 1-4 phase 3 trials Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Callis-Duffin, Kristina; Pinter, Andreas; Mease, Philip; Gisondi, Paolo; Yamauchi, Paul Steven; Yang, Ling; Levi, Eugenia; Kerdel, Francisco A.

publication date

  • December 1, 2020

webpage

category

start page

  • AB30

end page

  • AB30

volume

  • 83

issue

  • 6